SARS-CoV-2 spike and nucleocapsid proteins fail to activate human dendritic cells or γδ T cells.


Journal

PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081

Informations de publication

Date de publication:
2022
Historique:
received: 05 04 2022
accepted: 30 06 2022
entrez: 14 7 2022
pubmed: 15 7 2022
medline: 19 7 2022
Statut: epublish

Résumé

γδ T cells are thought to contribute to immunity against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), but the mechanisms by which they are activated by the virus are unknown. Using flow cytometry, we investigated if the two most abundant viral structural proteins, spike and nucleocapsid, can activate human γδ T cell subsets, directly or in the presence of dendritic cells (DC). Both proteins failed to induce interferon-γ production by Vδ1 or Vδ2 T cells within fresh mononuclear cells or lines of expanded γδ T cells generated from healthy donors, but the same proteins stimulated CD3+ cells from COVID-19 patients. The nucleocapsid protein stimulated interleukin-12 production by DC and downstream interferon-γ production by co-cultured Vδ1 and Vδ2 T cells, but protease digestion and use of an alternative nucleocapsid preparation indicated that this activity was due to contaminating non-protein material. Thus, SARS-CoV-2 spike and nucleocapsid proteins do not have stimulatory activity for DC or γδ T cells. We propose that γδ T cell activation in COVID-19 patients is mediated by immune recognition of viral RNA or other structural proteins by γδ T cells, or by other immune cells, such as DC, that produce γδ T cell-stimulatory ligands or cytokines.

Identifiants

pubmed: 35834480
doi: 10.1371/journal.pone.0271463
pii: PONE-D-22-10090
pmc: PMC9282473
doi:

Substances chimiques

Nucleocapsid Proteins 0
Receptors, Antigen, T-Cell, gamma-delta 0
Spike Glycoprotein, Coronavirus 0
spike protein, SARS-CoV-2 0
Interferon-gamma 82115-62-6

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

e0271463

Déclaration de conflit d'intérêts

The authors have declared that no competing interests exist.

Références

Front Immunol. 2017 Oct 27;8:1401
pubmed: 29163482
Biomed Pharmacother. 2020 Dec;132:110859
pubmed: 33120236
J Virol. 2011 Oct;85(19):10109-16
pubmed: 21752902
Nat Rev Immunol. 2020 Sep;20(9):515-516
pubmed: 32728221
Mil Med Res. 2021 Sep 7;8(1):49
pubmed: 34488908
J Immunol. 2006 Feb 1;176(3):1386-93
pubmed: 16424165
Clin Immunol. 2002 Jun;103(3 Pt 1):296-302
pubmed: 12173304
J Immunol. 2015 Jun 15;194(12):5953-60
pubmed: 25964489
Front Immunol. 2021 Mar 29;12:666983
pubmed: 33854516
Front Immunol. 2020 May 01;11:827
pubmed: 32425950
Front Immunol. 2019 Apr 26;10:913
pubmed: 31080452
Front Cell Infect Microbiol. 2020 May 19;10:233
pubmed: 32509601
Cells. 2020 Aug 27;9(9):
pubmed: 32867206
Microbes Infect. 2005 Mar;7(3):518-28
pubmed: 15777667
Nat Immunol. 2021 Jul;22(7):829-838
pubmed: 33963333
PLoS Pathog. 2021 Sep 16;17(9):e1009804
pubmed: 34529726
Nature. 2020 Aug;584(7821):457-462
pubmed: 32668444
J Exp Med. 2002 Dec 16;196(12):1575-84
pubmed: 12486100
J Cell Mol Med. 2020 Oct;24(19):11603-11606
pubmed: 32864865
Signal Transduct Target Ther. 2022 Mar 11;7(1):83
pubmed: 35277473
Cell Immunol. 2015 Jul;296(1):31-40
pubmed: 25991474
Nat Commun. 2020 Oct 16;11(1):5243
pubmed: 33067472
J Clin Immunol. 2020 Nov;40(8):1082-1092
pubmed: 32829467
J Med Virol. 2021 May;93(5):2735-2739
pubmed: 33506952
Science. 1998 Mar 13;279(5357):1737-40
pubmed: 9497295
Nat Microbiol. 2020 Oct;5(10):1185-1191
pubmed: 32908214
Cell. 2020 Jun 25;181(7):1489-1501.e15
pubmed: 32473127
JAMA. 2020 May 26;323(20):2052-2059
pubmed: 32320003
J Clin Invest. 1999 May 15;103(10):1437-49
pubmed: 10330426
Cell Res. 2021 Jul;31(7):818-820
pubmed: 33742149
Nat Rev Cancer. 2019 Jul;19(7):392-404
pubmed: 31209264
Signal Transduct Target Ther. 2021 Nov 3;6(1):382
pubmed: 34732709
Immunol Rev. 2020 Nov;298(1):74-83
pubmed: 33017054
J Infect Dis. 2006 May 1;193(9):1244-9
pubmed: 16586361
Blood. 2012 Apr 26;119(17):4013-6
pubmed: 22403253
J Infect Dis. 2009 Sep 15;200(6):858-65
pubmed: 19656068
Oncotarget. 2017 Jan 24;8(4):5954-5964
pubmed: 27992381
Cell Immunol. 2015 Jul;296(1):10-21
pubmed: 25659480
Eur J Clin Invest. 2021 Jan;51(1):e13443
pubmed: 33131070
Front Immunol. 2014 Dec 19;5:650
pubmed: 25566261
EBioMedicine. 2020 Jul;57:102885
pubmed: 32650275
Nat Rev Immunol. 2020 Jun;20(6):355-362
pubmed: 32376901
JCI Insight. 2021 Sep 22;6(18):
pubmed: 34375313
Scand J Immunol. 2009 Sep;70(3):245-55
pubmed: 19703014
Nat Med. 2020 Nov;26(11):1701-1707
pubmed: 32812012
J Exp Med. 2020 Dec 7;217(12):
pubmed: 32886755
J Transl Med. 2020 Jun 29;18(1):261
pubmed: 32600410
Nat Med. 2020 Jul;26(7):1017-1032
pubmed: 32651579
J Clin Immunol. 2005 May;25(3):230-7
pubmed: 15981088
J Immunol. 2005 Jan 1;174(1):252-60
pubmed: 15611247
Clin Transl Immunology. 2019 Sep 23;8(9):e1079
pubmed: 31559018
Cancer Immunol Immunother. 2010 Jul;59(7):1109-20
pubmed: 20306041
Cytotherapy. 2012 Feb;14(2):173-81
pubmed: 22029653
Nat Immunol. 2015 Nov;16(11):1114-23
pubmed: 26482978
Microorganisms. 2021 Aug 26;9(9):
pubmed: 34576716
Heliyon. 2021 Feb 02;7(2):e06187
pubmed: 33644468
J Immunol. 2009 Jan 15;182(2):1174-81
pubmed: 19124761

Auteurs

Kiran Singh (K)

Discipline of Immunology, Trinity Translational Medicine Institute, Trinity College Dublin, St. James's Hospital, Dublin, Ireland.

Sita Cogan (S)

Discipline of Immunology, Trinity Translational Medicine Institute, Trinity College Dublin, St. James's Hospital, Dublin, Ireland.

Stefan Elekes (S)

Discipline of Immunology, Trinity Translational Medicine Institute, Trinity College Dublin, St. James's Hospital, Dublin, Ireland.

Dearbhla M Murphy (DM)

Discipline of Immunology, Trinity Translational Medicine Institute, Trinity College Dublin, St. James's Hospital, Dublin, Ireland.

Sinead Cummins (S)

Discipline of Immunology, Trinity Translational Medicine Institute, Trinity College Dublin, St. James's Hospital, Dublin, Ireland.

Rory Curran (R)

Discipline of Immunology, Trinity Translational Medicine Institute, Trinity College Dublin, St. James's Hospital, Dublin, Ireland.

Zaneta Najda (Z)

Molecular Cell Biology Laboratory, Smurfit Institute of Genetics, Trinity College Dublin, Dublin, Ireland.

Margaret R Dunne (MR)

Discipline of Immunology, Trinity Translational Medicine Institute, Trinity College Dublin, St. James's Hospital, Dublin, Ireland.

Gráinne Jameson (G)

Discipline of Immunology, Trinity Translational Medicine Institute, Trinity College Dublin, St. James's Hospital, Dublin, Ireland.

Siobhan Gargan (S)

Discipline of Clinical Medicine, Trinity Translational Medicine Institute, Trinity College Dublin, St. James's Hospital, Dublin, Ireland.

Seamus Martin (S)

Molecular Cell Biology Laboratory, Smurfit Institute of Genetics, Trinity College Dublin, Dublin, Ireland.

Aideen Long (A)

Discipline of Clinical Medicine, Trinity Translational Medicine Institute, Trinity College Dublin, St. James's Hospital, Dublin, Ireland.

Derek G Doherty (DG)

Discipline of Immunology, Trinity Translational Medicine Institute, Trinity College Dublin, St. James's Hospital, Dublin, Ireland.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH